New Cannabis Therapies

By, Special for  USDR

Cannabinoid based companies within the medical marijuana community are pushing the industry forward through advancements in clinical trials, research, international patents and other forms of development to treat serious disorders including neurological and inflammatory issues such as chronic arthritis and many other special diseases.  Companies in the sector with current and recent achievements and milestones include: Cannabics Pharmaceuticals Inc. (OTC: CNBX), Vitality Biopharma, Inc. (OTC: VBIO), Cannabis Sativa (OTC: CBDS), GW Pharmaceuticals plc (NASDAQ: GWPH) and Terra Tech Corp. (OTC:  TRTC)

Vitality Biopharma, Inc. (OTCQB: VBIO), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the filing of an international PCT patent application, a milestone in its development of a platform of cannabinoid  pharmaceuticals.

Read the full Vitality Biopharma (VBIO) Press Release at:

The Patent Cooperation Treaty (PCT) is an international patent law treaty, which provides a unified procedure for filing patent applications to protect inventions in each of its member states. Vitality Biopharma’s patent filing includes details that were previously submitted in three separate U.S. provisional applications, and includes 79 patent claims and almost 200 individual compounds, including novel glycoside prodrugs of the most abundant phytocannabinoids, THC and cannabidiol (CBD), as well as a variety of other phytocannabinoids and endocannabinoids. The patent application includes additional compounds, such as vanilloids, a class of molecules that could provide sustained pain relief through targeting of the TRPV1 receptor, and enzymatic biosynthesis methods that the Company uses internally for drug  manufacturing.

There are 151 member countries within the PCT worldwide, so near global patent coverage can be obtained through successful patent prosecution in the U.S., Japan, Europe, Canada, Australia, New Zealand, China, Brazil, Russia, India, and many other countries.  The original priority date for this filing was September 22, 2015, therefore coverage of any underlying patent claims would extend for 20 years until 2035 in the United States, and may be subject to patent term extensions that would enable years of additional protection.  “This is a significant milestone enabled by our team’s discovery and production of a versatile new portfolio of cannabinoid pharmaceuticals,” said Robert Brooke, Chief Executive Officer of Vitality Biopharma. “The clinical data emerging on the use of cannabinoids for inflammatory bowel disease, opiate addiction, and many other serious disorders is inspiring, and our team is now working internally and through collaborators to develop key therapeutic applications for our  compounds.”

In other sector related market performances and developments of  note:

Cannabics Pharmaceuticals Inc. (OTC Pink: CNBX) announced in October that results from the company’s latest cancer HTS research overtly conclude that, depending upon the THC/CBD ratio, specific Cannabis extracts are directly contributive to reducing U87MG glioblastoma cell viability. The Company expects that results on additional types of cancers will be attained during December 2016.  “The Cannabics’ method of diagnosis clearly differentiates between a multitude of varied plant extracts and their apoptotic and necrotic effects by utilizing state of the art HTS (High Through-put Screening) on cells derived from patients’ biopsies; the results of which are visualized in “scans” of the before, during and after effect upon the cancer cells themselves” said Dr. Eyal Ballan, Chief Scientist of Cannabics Pharmaceuticals  Inc.

Cannabis Sativa (OTCQB: CBDS) closed up over 7% at $7.60 per share on Tuesday by the time the market closed. Cannabis Sativa, Inc., through its subsidiaries, develops, manufactures, and sells herbal based skin care products in the United States and internationally. It offers herbal based line of products, including Go Deep, a deep penetrating healing salve that reduces pain and inflammation when massaged into muscles, ligaments, tendons, and  joint .

GW Pharmaceuticals plc (NASDAQ: GWPH) closed up slightly on Tuesday closing at $120.25 on over 650,000 shares traded by the market close.  GW Pharmaceuticals, a biopharmaceutical company, together with its subsidiaries, engages in discovering, developing, and commercializing cannabinoid prescription  medicines.

Terra Tech Corp. (OTCQX: TRTC), a vertically integrated cannabis-focused agriculture company, last month announced that Blüm has been granted a license by the City of San Leandro, California, to open a new retail facility.  Blüm will work with San Leandro City staff to develop a commercial cannabis facility that meets the needs of the residents of San Leandro and the requirements of the City on the 13,000 square foot site, located at 1911 Fairway  Drive. is leading provider of third party publishing & news dissemination services.  If you would like more information regarding our news coverage solutions, please visit for more details.  Get an edge on the market with our Premium News Alerts that are FREE for a limited time at  Follow us on Facebook: and Twitter:

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNMG is NOT affiliated in any manner with any company mentioned herein.  FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNMG is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG has been compensated one thousand seven hundred dollars for news coverage of the current press release issued by Vitality Biopharma, Inc. by a non-affiliated third party.  FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS  RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such  statements.


All opinions expressed on USDR are those of the author and not necessarily those of US Daily Review.